In the last trading session, 1.07 million shares of the Stoke Therapeutics Inc (NASDAQ:STOK) were traded, and its beta was 1.01. Most recently the company’s share price was $7.74, and it changed around -$0.55 or -6.63% from the last close, which brings the market valuation of the company to $418.56M. STOK currently trades at a discount to its 52-week high of $17.58, offering almost -127.13% off that amount. The share price’s 52-week low was $6.29, which indicates that the current value has risen by an impressive 18.73% since then. We note from Stoke Therapeutics Inc’s average daily trading volume that its 10-day average is 1.02 million shares, with the 3-month average coming to 814.35K.
Stoke Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.22. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended STOK as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight.
Stoke Therapeutics Inc (NASDAQ:STOK) trade information
Instantly STOK has showed a red trend with a performance of -6.63% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 8.95 on recent trading dayincreased the stock’s daily price by 13.52%. The company’s shares are currently down -29.83% year-to-date, but still down -12.74% over the last five days. On the other hand, Stoke Therapeutics Inc (NASDAQ:STOK) is -8.94% down in the 30-day period. We can see from the shorts that 11.71 million shares have been sold at a short interest cover period of 15.6 day(s).
The consensus price target as assigned by Wall Street analysts is $18, which translates to bulls needing to increase their stock price by 57.0% from its current value. Analyst projections state that STOK is forecast to be at a low of $18 and a high of $18.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 1.74%. Stoke Therapeutics Inc earnings are expected to increase by 27.50% in 2025, but the outlook is negative -14.94% per year for the next five years.
STOK Dividends
Stoke Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-17.
Stoke Therapeutics Inc (NASDAQ:STOK)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.82% of Stoke Therapeutics Inc shares, and 108.25% of them are in the hands of institutional investors. The stock currently has a share float of 113.73%. Stoke Therapeutics Inc stock is held by 177.0 institutions, with SKORPIOS TRUST being the largest institutional investor. By 2024-06-30, it held 19.445% of the shares, which is about 10.84 million shares worth $146.5 million.
BLACKROCK INC., with 9.6998% or 5.41 million shares worth $73.08 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.57 shares worth $12.18 million, making up 2.91% of all outstanding shares. On the other hand, BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO held roughly 969.34 shares worth around $7.5 million, which represents about 1.79% of the total shares outstanding.
